VP, Exploratory Chemistry
Dr. Charlie Johannes joined FogPharma as Vice President Exploratory Chemistry in July 2021.
Dr. Johannes brings over 20 years experience in chemistry-driven platform technologies, a passion for therapeutic technology innovation, and a commitment to the development of new modalities, especially hyperstabilized alpha-helical peptides.
Prior to joining FogPharma, Dr. Johannes was a Principal Investigator for the Peptide Engineering Program (PEP) at A*STAR and lead research collaborations with MSD on peptide permeability and worked in the Disease Intervention Technology Lab. Through these experiences, Dr. Johannes targeted a multitude of macromolecular interactions such as p53, Bcl-2, eIF4E, and KRAS. Dr. Johannes also co-founded the Peptides and Proteins Society Singapore (P2S2) and served as the first President of the society from 2018-2021. Prior to this, he developed 2 separate diversity-oriented platforms at Infinity Pharmaceuticals and Forma Therapeutics in a global role which generated over $50 million in revenue and led external collaborations and seamlessly supported medicinal chemistry efforts to fill the pipelines. As part of his global role, Dr. Johannes moved to Singapore and eventually left as Director and site head at Forma Therapeutics as Head of Organic Chemistry division at the Agency for Science Technology and Research (A*STAR). Dr. Johannes was responsible for directing a group of over 50 scientists in the total synthesis of natural products, development of enantioselective methodologies, drug discovery, medicinal chemistry, and process research. Dr. Johannes also served as an adjunct Assistant Professor of Chemistry at Nanyang Technological University with joint appointments at the Experimental Therapeutics Center and Experimental Drug Discovery Center.
Dr. Johannes was trained as a synthetic organic chemist and earned his Ph.D. at Boston College. He turned down his postdoctoral studies at Cambridge University to join the New Leads Group at EISAI and rapidly advanced natural product based therapeutic leads. Dr. Johannes has over 50 publications and numerous patents.